Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
26
10
2018
medline:
2
6
2021
entrez:
26
10
2018
Statut:
ppublish
Résumé
Recognition of neuroendocrine differentiation is important for tumor classification and treatment stratification. To detect and confirm neuroendocrine differentiation, a combination of morphology and immunohistochemistry is often required. In this regard, synaptophysin, chromogranin A, and CD56 are established immunohistochemical markers. Insulinoma-associated protein 1 (INSM1) has been suggested as a novel stand-alone marker with the potential to replace the current standard panel. In this study, we compared the sensitivity and specificity of INSM1 and established markers. A cohort of 493 lung tumors including 112 typical, 39 atypical carcinoids, 77 large cell neuroendocrine carcinomas, 144 small cell lung cancers, 30 thoracic paragangliomas, 47 adenocarcinomas, and 44 squamous cell carcinomas were selected and tissue microarrays were constructed. Synaptophysin, chromogranin A, CD56, and INSM1 were stained on all cases and evaluated manually as well as with an analysis software. Positivity was defined as ≥1% stained tumor cells in at least 1 of 2 cores per patient. INSM1 was positive in 305 of 402 tumors with expected neuroendocrine differentiation (typical and atypical carcinoids, large cell neuroendocrine carcinomas, small cell lung cancers, and paraganglioma; sensitivity: 76%). INSM1 was negative in all but 1 of 91 analyzed non-neuroendocrine tumors (adenocarcinomas, squamous cell carcinomas; specificity: 99%). All conventional markers, as well as their combination, had a higher sensitivity (97%) and a lower specificity (78%) for neuroendocrine differentiation compared with INSM1. Although INSM1 might be a meaningful adjunct in the differential diagnosis of neuroendocrine neoplasias, a general uncritical vote for replacing the traditional markers by INSM1 may not be justified.
Identifiants
pubmed: 30358615
doi: 10.1097/PAI.0000000000000715
pii: 00129039-202003000-00009
doi:
Substances chimiques
CD56 Antigen
0
CHGA protein, human
0
Chromogranin A
0
NCAM1 protein, human
0
Neoplasm Proteins
0
Repressor Proteins
0
SYP protein, human
0
Synaptophysin
0
INSM1 protein, human
147955-03-1
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-242Références
Inamura K. Update on immunohistochemistry for the diagnosis of lung cancer. Cancers. 2018;10:3.
Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46:195–201.
Hamanaka W, Motoi N, Ishikawa S, et al. A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy. Hum Pathol. 2014;45:1045–1056.
Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–1197.
Doxtader EE, Mukhopadhyay S. Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. Cancer Cytopathol. 2018;126:243–252.
Rooper LM, Sharma R, Li QK, et al. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol. 2017;41:1561–1569.
Goto Y, De Silva MG, Toscani A, et al. A novel human insulinoma-associated cDNA, IA-1, encodes a protein with “zinc-finger” DNA-binding motifs. J Biol Chem. 1992;267:15252–15257.
Rosenbaum JN, Guo Z, Baus RM, et al. INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol. 2015;144:579–591.
Dermawan JK, Mukhopadhyay S. Insulinoma-associated protein 1 (INSM1) differentiates carcinoid tumourlets of the lung from pulmonary meningothelial-like nodules. Histopathology. 2018;72:1067–1069.
Kuji S, Watanabe R, Sato Y, et al. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: analysis of 37 cases. Gynecol Oncol. 2017;144:384–390.
Xue W, Xin Z, Zhang Y, et al. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol. 2018;79:151–159.
Tanigawa M, Nakayama M, Taira T, et al. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol. 2018;51:32–40.
Rooper LM, Bishop JA, Westra WH. INSM1 is a sensitive and specific marker of neuroendocrine differentiation in head and neck tumors. Am J Surg Pathol. 2018;42:665–671.
Ames HM, Rooper LM, Laterra JJ, et al. INSM1 expression is frequent in primary central nervous system neoplasms but not in the adult brain parenchyma. J Neuropathol Exp Neurol. 2018;77:374–382.
Yoshida A, Makise N, Wakai S, et al. INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod Pathol. 2018;31:744–752.
Rush PS, Rosenbaum JN, Roy M, et al. Insulinoma-associated 1: a novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). J Cutan Pathol. 2018;45:129–135.
Travis WDBE, Burke AP, Marx A, et alTravis WD, BE, Burke AP, Marx A, Nicholson AG. Terminology and criteria in non-resection specimens. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. Lyon: IARC Publication; 2015:17–21.
Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology. 2012;61:1017–1025.
Lisenko K, Leichsenring J, Zgorzelski C, et al. Qualitative comparison between carrier-based and classical tissue microarrays. Applied immunohistochemistry and molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 2017.
Kriegsmann M, Harms A, Longuespee R, et al. Role of conventional immunomarkers, HNF4-a, and SATB2 in the differential diagnosis of pulmonary and colorectal adenocarcinomas. Histopathology. 2018;72:997–1006.
Kriegsmann M, Muley T, Harms A, et al. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases. Diagn Pathol. 2015;10:210.
Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
Tanaka Y, Ogawa H, Uchino K, et al. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. J Thorac Cardiovasc Surg. 2013;145:839–846.
Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28:1373–1378.
Thunnissen E, Borczuk AC, Flieder DB, et al. The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. an international reproducibility study in a demanding set of cases. J Thorac Oncol. 2017;12:334–346.
Rodriguez EF, Chowsilpa S, Maleki Z. Insulinoma-associated protein 1 immunostain: a diagnostic tool for pulmonary small cell carcinoma in cytology. Acta Cytol. 2018. [Epub ahead of print].
McColl K, Wildey G, Sakre N, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget. 2017;8:73745–73756.